Rheumatoid Arthritis

Rheumatic and myocardial inflammation can be treated with disease modifying anti-rheumatic drugs.

Rapid reduction of rheumatoid arthritis symptoms rated as the most important factor in choosing a treatment.

Patients with early stage rheumatoid arthritis may benefit from tapering DMARD therapy.

Naturally-occurring genetic variants may improve autoimmune disease treatment.

Biosimilars can provide an easily accessible, low cost treatment option for patients with rheumatoid arthritis.

Baricitinib is a once-daily oral selective JAK1 and JAK2 inhibitor for the treatment of autoimmune and inflammatory diseases.

Ingredient in aspirin combined with popular diabetes drug can turn off faulty protein that plays a key role in inflammatory diseases, such as rheumatoid arthritis.

Growing evidence points to the relationship between rheumatoid arthritis and heart problems.

IL-1 antagonists are traditionally used to treat patients with rheumatoid diseases.

Two TNF-inhibitors found equally effective treating RA patients.

Researchers able to predict treatment response to TNFI drugs and rituximab in RA patients.

Growing evidence points to the relationship between rheumatoid arthritis and heart problems.

Patients with rheumatoid arthritis want a fast-acting, orally administered treatment for their symptoms.

A better understanding of the mechanisms of arthritis is needed to develop superior treatments.

Baricitinib significantly improved patient-reported outcomes in individuals with RA.

Study compares the safety and efficacy of sarilumab with adalimumab in patients who cannot tolerate methotrexate.

Baricitinib is a once-daily oral selective JAK1 and JAK2 inhibitor for the treatment of autoimmune and inflammatory diseases.

Sarilumab shows promise on circulating biomarkers of bone and joint destruction in patients with rheumatoid arthritis who had shown an inadequate response to methotrexate.

New guidelines for rheumatoid arthritis treatment discussed at ACR conference.

ACR session reinforces the need for new research about how the genome, epigenome, and other factors play a role in rheumatoid arthritis.

There is building consensus that multiple sclerosis and rheumatoid arthritis display similar autoimmune genetic pathways.

Cox-2 inhibitors carry risk for arthritis patients with heart disease.

Top news of the day from across the health care landscape.

Patients who live with rheumatoid arthritis do not die from swollen joints but face twice the risk of suffering a heart attack or stroke.

The 12-biomarker test is gaining acceptance among rheumatologists and was recently added to a clinical guideline.

New therapeutic targets provide hope for targeted treatments for rheumatoid diseases.

JAK inhibitors may be more effective than older biologic drugs in certain patients.

A recent review outlines the best treatment option to prevent bone loss associated with rheumatoid arthritis.

Patients taking baricitinib saw improvements in rheumatoid arthritis symptoms as soon as a week into treatment.

Orencia is the only CTLA-4lg approved in the United States, European Union, and Japan for the treatment of rheumatoid arthritis.